SEC Issues Formal Order Related to Possible Prohibited Payments Made Immucor
Immucor, Inc., which sells reagents and systems used to identify the properties of blood prior to a transfusion, issued a press release on Friday stating that the Securities and Exchange Commission (SEC) had issued a formal order in an investigation related to payments made by the company's Italian subsidiary to individuals associated with government medical facilities. The formal order allows the Staff of the SEC to compel testimony and document production from Immucor. The SEC's investigation commenced after Immucor voluntarily disclosed to the SEC a possible violation of the books and records requirements of the Foreign Corrupt Practices Act (FCPA).
|posted by Douglas N. Jacobson| Permalink 
